This is a working overview of modified GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
In November 2022, it was announced that McDonald's was leaving Belarus on 22 November and that the Russian fast food chain Vkusno i tochka would take its place. However, this did not happen, and the operations of McDonald's was extended until 27 November; since then, the restaurants operated under the sign "We are open!" (Russian: Мы открыты!, IPA: [ˌmɨ ɐtˈkrɨtɨ]). In early April 2023, KSB Victory Restaurants (Russian: КСБ Виктори Рестораны, IPA: [ˌkaɛzˈbɛ vʲɪkˈtorʲɪ rʲɪstɐˈranɨ]), operators of McDonald's in the country, filed an application for registration of the name and trademark "Mak.by". On April 18, 2023, the restaurant chain was renamed Mak.by.
== Structure and active site == Apamin is a polypeptide possessing an amino acid sequence of H-Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 (one-letter sequence CNCKAPETALCARRCQQH-NH2, with disulfide bonds between Cys1-Cys11 and Cys3-Cys15). Apamin is very rigid because of the two disulfide bridges and seven hydrogen bonds. The three-dimensional structure of apamin has been studied with several spectroscopical techniques: HNMR, Circular Dichroism, Raman spectroscopy, FT-IR. The structure is presumed to consist of an alpha-helix and beta-turns, but the exact structure is still unknown. By local alterations it is possible to find the amino acids that are involved in toxicity of apamin. It was found by Vincent et al. that guanidination of the ε-amino group of lysine4 does not decrease toxicity. When the ε-amino group of lysine4 and the α-amino group of cysteine1 are acetylated or treated with fluorescamine, toxicity decreases with a factor of respectively 2.5 and 2.8. This is only a small decrease, which indicates that neither the ε-amino group of lysine4 nor the α-amino group of cysteine1 is essential for the toxicity of apamin. Glutamine7 was altered by formation of an amide bond with glycine ethyl ester, this resulted in a decrease in toxicity of a factor 2.0. Glutamine7 also doesn't appear to be essential for toxicity. When histidine18 is altered by carbethoxylation, toxicity decreases only by a factor 2.6.
== Genetics == Four alternatively spliced transcript variants encoding two distinct isoforms have been observed. There is also evidence for alternative translation initiation from non-AUG (CUG and GUG) start sites, in-frame and downstream of the initiator AUG codon, to give rise to nuclear forms of this hormone.
== Further reading == Beasley, Norman (1956). The Continuing Spirit. New York: Duell, Sloan and Pearce. Braden, Charles S. (1958). Christian Science Today. Dallas: Southern Methodist University Press.
Sources: en.wikipedia.org
== Other related drugs == 5-Chloro-AMT (PAL-542) – serotonin–dopamine releasing agent (SDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor 5-Fluoro-AMT (PAL-212; PAL-544) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin receptor agonist, and monoamine oxidase A (MAO-A) inhibitor CPI-CG-8 – serotonin 5-HT2C receptor agonist Methocinnamox (MCAM) – long-lasting irreversible μ-opioid receptor antagonist Methoclocinnamox (MCCAM; NIH-10420) – long-lasting irreversible μ-opioid receptor partial agonist Oxa-noribogaine – atypical κ-opioid receptor agonist (noribogaine analogue) SR-17018 (SR17018; SR-17; SR17; SR) – μ-opioid receptor biased agonist
== Sources == Bulletins of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom Savinkov, Boris. The Fight Against the Bolsheviks // Russian Foreign Literature. Anthology in Six Volumes. Moscow: Kniga, 1990. Vol. 1, Book 2. The Union for the Defense of the Homeland and Freedom and the Yaroslavl Rebellion of 1918 // Proletarian Revolution, 1923, no. 10. Klementyev, V. F. In Bolshevik Moscow (1918–1920). Moscow: Russkiy Put, 1998. Korovin, V. V.; Rusanov, E. P. Boris Savinkov's Case // History of the Soviet Union, 1967, no. 6, pp. 143–155. Golinkov, D. L. The Collapse of the Enemy Underground. Moscow, 1971. Gopper, Karl. Four Collapses: Memoirs of General Gopper. Riga, 1920. Jekabsons, E.; Ščerbinskis, V. Participation of Latvians in White Military Forces During the Russian Civil War 1917–1920. Riga: Journal of the Latvian Institute of History, 1997. Shentalinsky, Vitaly. "His Among His Own. Savinkov in the Lubyanka." New World, no. 7 (1996).
There is debate as to whether the Kingdom of Poland, as a state, was formally replaced by the Vistula Land. Towns were stripped of their charters in reprisal and turned into villages. The Russian Partition of Poland was made an official province of the Russian Empire in 1867. In the early 20th century, a major part of the Russian Revolution of 1905 was the Revolution in the Kingdom of Poland (1905–1907). The return to Poland's independence was a result of the First World War on the Polish lands (1914–1918), the overthrow of the Tsarist regime, and the defeat of the Central Powers in 1918.
Sources: en.wikipedia.org
== Properties == The physical and chemical properties of magnetic nanoparticles largely depend on the synthesis method and chemical structure. In most cases, the particles range from 1 to 100 nm in size and may display superparamagnetism.
=== Analogs === Some analog substances have been created which mimic caffeine's properties with either function or structure or both. Of the latter group are the xanthines DMPX and 8-chlorotheophylline, which is an ingredient in dramamine. Members of a class of nitrogen substituted xanthines are often proposed as potential alternatives to caffeine. Many other xanthine analogues constituting the adenosine receptor antagonist class have also been elucidated. Some other caffeine analogs:
=== Diarrhea === Opium tincture is indicated for the treatment of severe fulminant (intense, prolific) diarrhea that does not respond to standard therapy (e.g., Imodium or Lomotil). The usual starting dose is 0.3 mL to 0.6 mL (about six to 12 drops) in a glass of water or juice four times a day. Refractory cases (such as diarrhea resulting from the complications of HIV/AIDS) may require higher than normal dosing, for example, 1 to 2 mL every 3 hours, for a total daily dose of up to 16 mL a day. In terminal diseases, there is no ceiling dose for opium tincture; the dose is increased slowly until diarrhea is controlled.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.